Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more
Apellis Pharmaceuticals Inc (APLS) - Total Liabilities
Latest total liabilities as of December 2025: $705.11 Million USD
Based on the latest financial reports, Apellis Pharmaceuticals Inc (APLS) has total liabilities worth $705.11 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Apellis Pharmaceuticals Inc - Total Liabilities Trend (2013–2025)
This chart illustrates how Apellis Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Apellis Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Apellis Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mitie Group plc
PINK:MITFF
|
USA | $2.05 Billion |
|
Recordati Industria Chimica e Farmaceutica S.p.A.
PINK:RICFY
|
USA | $3.37 Billion |
|
Feilong Auto Components Co Ltd
SHE:002536
|
China | CN¥2.28 Billion |
|
Pilgrims Pride Corp
NASDAQ:PPC
|
USA | $6.65 Billion |
|
Tibet Mineral Development Co Ltd
SHE:000762
|
China | CN¥3.59 Billion |
|
Shaanxi Sirui Advanced Materials Co. Ltd. A
SHG:688102
|
China | CN¥1.23 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Apellis Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apellis Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apellis Pharmaceuticals Inc (2013–2025)
The table below shows the annual total liabilities of Apellis Pharmaceuticals Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $705.11 Million | +7.40% |
| 2024-12-31 | $656.51 Million | +10.49% |
| 2023-12-31 | $594.21 Million | +0.65% |
| 2022-12-31 | $590.35 Million | -13.58% |
| 2021-12-31 | $683.10 Million | -9.64% |
| 2020-12-31 | $756.01 Million | +112.95% |
| 2019-12-31 | $355.02 Million | +734.13% |
| 2018-12-31 | $42.56 Million | +28.24% |
| 2017-12-31 | $33.19 Million | +812.04% |
| 2016-12-31 | $3.64 Million | +13.71% |
| 2015-12-31 | $3.20 Million | +195.89% |
| 2014-12-31 | $1.08 Million | +59.76% |
| 2013-12-31 | $676.96K | -- |